EUCTR2013-002646-36-SK进行中（未招募）1 期
PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB(PF-04950615), IN REDUCING THEOCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 17,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed Consent
- •There must be evidence of personally signed and dated, informed
- •consent documents for both the pre-screening and screening visits
- •indicating that the subject (or a legal representative) has been informed
- •of all pertinent aspects of the study. The pre-screening visit informed
- •consent form will be limited to study activities up until the screening
- •visit. The screening visit informed consent form will cover all aspects of
- •the study.2. Compliance
- •Subjects must be willing and able to comply with scheduled visits,
- •treatment plan, laboratory tests, and other study procedures.
- •For subjects who have had a prior CVD event, subjects must be men or
- •women age = the legal age of majority (legal adulthood), in the subject's
- •country.For subjects who have not had a prior CVD event, men must be age =50
- •years and women must be age = 60 years.
- •4. Acceptance of administration of investigational product
- •Subjects must be willing and able to self-administer or be administered
- •sub-cutaneous injections of investigational product.
- •5. Requirements for background lipid lowering treatment
- •There should be no plans at the time of screening and randomization to
- •modify the dose of statin for the duration of the trial. Unless the
- •background lipid lowering treatment exceptions described below are
- •met, subjects must be treated with one of the following highly effective
- •statins at the specified daily doses for = 6 weeks prior to the screening
- •atorvastatin, 40 or 80 mg once a day;
- •rosuvastatin, 20 or 40 mg, once a day;
- •simvastatin, 40 mg, once a day or, if a subject has been on that dose for
- •> 1 year, 80 mg, once a day.
- •Combination medications that contain atorvastatin, rosuvastatin, or
- •simvastatin components described at the aforementioned doses will be
- •permitted. Background lipid lowering treatment exceptions The following
- •background lipid lowering treatment exceptions are permitted:
- •- Lower doses of statins due to partial statin intolerance
- •Subjects may be on a lower dose of one of the highly effective statins
- •described above if there is documented intolerance to any one of them
- •(atorvastatin, rosuvastatin, or simvastatin) at the aforementioned doses.
- •Intolerance to any dose of any statin must be documented as historical
- •adverse events attributed to the statin in question, in the source
- •documentation and case report form (CRF).
- •-Regulatory limitations
- •Subjects may be on a lower dose of one of the highly effective statins
- •described above if the highest locally approved dose for one of the
- •stated statins is lower than those doses shown above (eg, in Japan,
- •atorvastatin 20 mg, once a day, is the highest locally approved dose).
- •Alternative statins
- •Subjects may be treated with other statins (pravastatin, fluvastatin,
- •pitavastatin, or lovastatin), different from the highly effective statins
- •listed above, if there is documented intolerance to any two different
- •highly effective statins (atorvastatin, rosuvastatin, simvastatin) at the
- •lowest available dose, for at least one of those highly effective statins.
- •Intolerance to any statin must be documented as historical adverse
- 另有 5 项未显示
排除标准
- •1. Personnel involved in the conduct of the study
- •Subjects who are investigational site staff members directly involved in
- •the conduct of the trial and their family members, site staff members
- •otherwise supervised by the Investigator, or subjects who are Pfizer
- •employees directly involved in the conduct of the trial.
- •2. Exclusionary prior CV events or planned revascularization procedures
- •-A planned coronary (PCI or CABG) or other arterial revascularization;
- •-Myocardial infarction, stroke, or any non-coronary arterial
- •revascularization = 30 days prior to screening;
- •-PCI = 90 days prior to screening.
- •3. Participation in prior clinical research studies
- •Participation in other studies involving small molecule investigational
- •drug(s) (Phases 1-4) within 1 month, or five half-lives, of Visit 1,
- •whichever is longer; any participation in a cholesteryl ester transfer
- •protein (CETP) inhibitor trial for any length of time; or any biological
- •agents within 6 months or 5 half-lives, of Visit 1, whichever is longer
- •(the investigator should refer to documents provided by the subject on
- •the other study to determine the investigational product half-life). If the
- •blind of the prior study has been broken and the investigator provides
- •documentation that the subject received placebo, the potential subject
- •can be included, regardless of when participation occurred.
- •4. Other exclusionary conditions
- •Other severe, acute, or chronic medical or psychiatric condition or
- •laboratory abnormality that may increase the risk associated with study
- •participation or investigational product administration or may interfere
- •with the interpretation of study results and, in the judgment of the
- •investigator, would make the subject inappropriate for entry into this
- •5. Childbearing potential and/or breast feeding
- •Pregnant females; breastfeeding females; and male and female subjects
- •who (with their partners) are of childbearing potential, who are
- •unwilling or unable to use a highly effective method of contraception asoutlined in this protocol for the duration of the study and for 63 days
- •after last dose of investigational product (refer to Section 4.4.2).
- •6. Latex sensitivity
- •Latex sensitive individuals (due to potential for exposure to natural dry
- •rubber in the prefilled syringe cap of investigational product, during
- •administration).
- •7. Apheresis
- •Undergoing lipid apheresis, within 6 weeks of screening, or planned start
- •of lipid apheresis.
- •8. Severe congestive heart failure
- •Congestive heart failure of New York Heart Association (NYHA) Class IV,
- •or if there is prior documentation of left ventricular ejection fraction
- •(LVEF) of < 25%, measured by imaging.
- •9. Dialysis
- •Potential subjects with end stage renal disease on dialysis.
- •10. Chronic renal insufficiency
- •Potential subjects with an eGFR of < 30 ml/min/1.73m2 by MDRD
- •formula at Visit 1.
- •11. Hypertension
- •Poorly controlled hypertension at any screening visit or at
- 另有 9 项未显示
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 multi-centre study to test the efficacy, safety and tolerability of Bococizumab (PF-04950615) administered subcutaneously in reducing the occurrence ofmajor cardiovascular events due to clogging up of arteries by fatty substances in high risk subjects.atherosclerosisEUCTR2013-002795-41-NLPfizer Inc., 235 East 42nd Street, New York, ny 1001711,000
进行中（未招募）
1 期
A Phase 3 multi-centre study to test the efficacy, safety and tolerability of Bococizumab (PF-04950615) administered subcutaneously in reducing the occurrence of major cardiovascular events due to clogging up of arteries by fatty substances in high risk subjects.MedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866atherosclerosisEUCTR2013-002646-36-PLPfizer Inc., 235 East 42nd Street, New York, NY 1001717,000
进行中（未招募）
1 期
A Phase 3 multi-centre study to test the efficacy, safety and tolerability of bococizumab (PF-04950615) administered subcutaneously in reducing the occurrence of major cardiovascular events due to clogging up of arteries by fatty substances in high risk subjects.MedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866atherosclerosisEUCTR2013-002795-41-DKPfizer Inc., 235 East 42nd Street, New York, ny 1001711,000
进行中（未招募）
1 期
A Phase 3 multi-centre study to test the efficacy, safety and tolerability of Bococizumab (PF-04950615) administered subcutaneously in reducing the occurrence of major cardiovascular events due to clogging up of arteries by fatty substances in high risk subjects.MedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866atherosclerosisEUCTR2013-002646-36-SEPfizer Inc., 235 East 42nd Street, New York, ny 1001717,000
进行中（未招募）
1 期
A Phase 3 multi-centre study to test the efficacy, safety and tolerability of Bococizumab (PF-04950615) administered subcutaneously in reducing the occurrence of major cardiovascular events due to clogging up of arteries by fatty substances in high risk subjects.MedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866atherosclerosisEUCTR2013-002646-36-BEPfizer Inc., 235 East 42nd Street, New York, ny 1001717,000